Plain-English translation of NCT07110415 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether Yangxinshi tablets, a Chinese herbal medicine, can help people with coronary heart disease (blocked arteries of the heart) who also have a weakened heart. Half of the participants will take the medication along with their regular treatment, while the other half will continue with standard treatment alone. The study will measure whether the medication reduces serious heart-related events and improves how well people can exercise and feel.
Many people with coronary heart disease develop heart weakness, which can be life-threatening and hard to manage with standard treatments alone. This trial is testing whether this medication can reduce serious events like heart attacks, strokes, and hospitalizations in this group of patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either take the medication or continue with your regular treatment only. Those taking the medication will take 3 tablets, three times a day, along with your standard heart disease treatments. The study will continue until enough serious heart events have occurred or the study ends, which could take months or longer. You will have regular check-ups to monitor your heart health, exercise ability, and overall quality of life.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China